JP2018520147A5 - - Google Patents

Download PDF

Info

Publication number
JP2018520147A5
JP2018520147A5 JP2017567249A JP2017567249A JP2018520147A5 JP 2018520147 A5 JP2018520147 A5 JP 2018520147A5 JP 2017567249 A JP2017567249 A JP 2017567249A JP 2017567249 A JP2017567249 A JP 2017567249A JP 2018520147 A5 JP2018520147 A5 JP 2018520147A5
Authority
JP
Japan
Prior art keywords
formula
diacid
crystal
pharmaceutical composition
ratio
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017567249A
Other languages
English (en)
Japanese (ja)
Other versions
JP6929234B2 (ja
JP2018520147A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/039572 external-priority patent/WO2016210418A1/en
Publication of JP2018520147A publication Critical patent/JP2018520147A/ja
Publication of JP2018520147A5 publication Critical patent/JP2018520147A5/ja
Application granted granted Critical
Publication of JP6929234B2 publication Critical patent/JP6929234B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017567249A 2015-06-25 2016-06-27 医薬共結晶組成物及びその用途 Expired - Fee Related JP6929234B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562184591P 2015-06-25 2015-06-25
US62/184,591 2015-06-25
PCT/US2016/039572 WO2016210418A1 (en) 2015-06-25 2016-06-27 Pharmaceutical co-crystal composition and use thereof

Publications (3)

Publication Number Publication Date
JP2018520147A JP2018520147A (ja) 2018-07-26
JP2018520147A5 true JP2018520147A5 (enExample) 2019-07-18
JP6929234B2 JP6929234B2 (ja) 2021-09-01

Family

ID=57586692

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017567249A Expired - Fee Related JP6929234B2 (ja) 2015-06-25 2016-06-27 医薬共結晶組成物及びその用途

Country Status (8)

Country Link
US (3) US10428099B2 (enExample)
EP (1) EP3297640A4 (enExample)
JP (1) JP6929234B2 (enExample)
KR (1) KR20180021805A (enExample)
CN (2) CN116854745A (enExample)
AU (1) AU2016284816B2 (enExample)
CA (1) CA2989001A1 (enExample)
WO (1) WO2016210418A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6851989B2 (ja) * 2015-05-18 2021-03-31 シン−ナット プロダクツ エンタープライズ エルエルシー 医薬用共結晶及びその用途
JP6768716B2 (ja) 2015-06-19 2020-10-14 シン−ナット プロダクツ エンタープライズ エルエルシー カルボプラチンベースの共結晶の医薬組成物及びその用途
US10980768B2 (en) 2015-06-19 2021-04-20 Syn-Nat Products Enterprise LLC Composition containing carboplatin and use
JP6929234B2 (ja) 2015-06-25 2021-09-01 シン−ナット プロダクツ エンタープライズ エルエルシー 医薬共結晶組成物及びその用途
CA3082295A1 (en) * 2017-11-21 2019-05-31 Medoncare Pharmaceutical Co., Ltd Combination products containing dicycloplatin, preparation and use thereof
WO2020043144A1 (zh) * 2018-09-01 2020-03-05 北京硕佰医药科技有限责任公司 一种铂类化合物磷酸盐及其制备方法
CN111205332B (zh) * 2020-02-25 2025-03-21 华东理工大学 奥沙利铂-黄酮药物共晶及其制备方法和应用
CN118302161A (zh) * 2021-11-26 2024-07-05 湖南湘源美东医药科技有限公司 含有铂类药物或者铂类药物共晶的药物组合物及其用途
CN116143705B (zh) * 2023-04-11 2023-06-30 齐泽(云南)生物科技有限公司 一种药用化合物
CN116217628B (zh) * 2023-05-08 2023-07-14 华东理工常熟研究院有限公司 奥沙利铂Pt(IV)配合物的共晶及其制备方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5922689A (en) 1995-09-11 1999-07-13 Unitech Pharmaceuticals, Inc. Cisplatin analogs for cancer treatment
US6297245B1 (en) 1998-08-04 2001-10-02 Unitech Pharmaceuticals Cisplatin and folic acid administered to treat breast cancer
KR100317473B1 (ko) * 1999-05-11 2001-12-22 이계호 신규의 백금(ｉｖ)착제 및 그 제조방법
CN1121380C (zh) * 2000-03-03 2003-09-17 北京兴大豪斯科技有限公司 一种抗肿瘤的双二羧酸二氨络铂衍生物及其药物组合物
AUPQ641100A0 (en) 2000-03-23 2000-04-15 Australia Nuclear Science & Technology Organisation Methods of synthesis and use of radiolabelled platinum chemotherapeutic ag ents
EP1473298B1 (en) 2001-11-30 2009-05-13 Jingzun Wang Supermolecular carboplatinum derivatives, their preparation and pharmaceutical composition containing them as active ingredient and applications of the compositions
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
CN1681495B (zh) 2002-08-19 2010-05-12 辉瑞产品公司 用于治疗过度增生性疾病的组合物
CA2514092C (en) * 2003-01-21 2013-03-19 S.S.C.I., Inc. Novel cocrystallization of hydrochloric acid salt of an active agent
CA2514733A1 (en) * 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
WO2004099224A1 (de) 2003-05-05 2004-11-18 Universität Regensburg Carboplatin-artige platin (ii)- komplexe
ATE453653T1 (de) 2003-08-13 2010-01-15 Univ South Florida Platinkomplexe zur behandlung von tumoren
CN101972240B (zh) * 2003-09-04 2012-07-25 赛福伦公司 莫达芬尼组合物
JP2007516259A (ja) * 2003-12-09 2007-06-21 メッドクリスタルフォームズ、エルエルシー 活性剤との混合相共結晶の調製方法
AU2006207321B2 (en) 2005-01-21 2012-09-06 Astex Therapeutics Limited Pharmaceutical compounds
EP1979369A1 (en) 2006-01-30 2008-10-15 Platco Technologies (Proprietary) Limited Preparation of platinum (ll) complexes
WO2008016702A2 (en) 2006-08-02 2008-02-07 Sunesis Pharmaceuticals, Inc. Combined use of (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1(2-thiazolyl)-1,8-naphthyridine-3-carboxylic
WO2010029577A2 (en) 2008-09-15 2010-03-18 Ganga Raju Gokaraju Anti-cancer drugs and uses relating thereto for metastatic malignant melanoma and other cancers
CZ302618B6 (cs) 2009-09-10 2011-08-03 Univerzita Palackého Cyklobutan-1,1-dikarboxylátokomplexy platiny s deriváty N6-benzyladeninu, zpusoby jejich prípravy a použití techto komplexu jako léciv v protinádorové terapii
EP2512522A4 (en) * 2009-12-16 2013-09-25 Brigham & Womens Hospital PARTICLES FOR ADMINISTRATION OF MULTIPLE AGENTS
US20110287110A1 (en) 2010-04-23 2011-11-24 Mark Wesley Dewhirst Combination cancer treatment
CN102863474A (zh) * 2011-07-09 2013-01-09 陈小平 一类治疗细胞增殖性疾病的铂化合物、其制备方法和应用
JP5179628B2 (ja) 2011-07-15 2013-04-10 ユニーテック株式会社 ４価白金錯体及びそれを含む医薬組成物
CN102993239A (zh) * 2011-09-19 2013-03-27 陈小平 离去基团含氨基或烷胺基的丁二酸衍生物的铂类化合物
US9220705B2 (en) 2013-03-07 2015-12-29 James David Hoeschele Method of treating colorectal cancer
ES2705342T3 (es) 2013-10-17 2019-03-22 Vertex Pharma Co-cristales de (S)-N-metil-8-(1-((2'-metil-[4,5'-bipirimidin]-6-il)amino)propan-2-il)quinolin-4-carboxamida y derivados deuterados de la misma como inhibidores de DNA-PK
CN104127402B (zh) 2014-08-15 2019-08-30 北京默加农生物技术发展有限公司 双环铂在制备抗病毒药物和抗菌药物中的应用
CA2981158C (en) * 2015-04-10 2022-05-24 Syn-Nat Products Enterprise LLC Process for the preparation of dicycloplatin
WO2016172393A1 (en) 2015-04-22 2016-10-27 Syn-Nat Products Enterprise LLC Co-crystal composition and its pharmaceutical use
JP6851989B2 (ja) * 2015-05-18 2021-03-31 シン−ナット プロダクツ エンタープライズ エルエルシー 医薬用共結晶及びその用途
JP6768716B2 (ja) 2015-06-19 2020-10-14 シン−ナット プロダクツ エンタープライズ エルエルシー カルボプラチンベースの共結晶の医薬組成物及びその用途
US10980768B2 (en) 2015-06-19 2021-04-20 Syn-Nat Products Enterprise LLC Composition containing carboplatin and use
JP6929234B2 (ja) 2015-06-25 2021-09-01 シン−ナット プロダクツ エンタープライズ エルエルシー 医薬共結晶組成物及びその用途

Similar Documents

Publication Publication Date Title
JP2018520147A5 (enExample)
JP6606692B2 (ja) （２Ｒ，５Ｓ，１３ＡＲ）−８−ヒドロキシ−７，９−ジオキソ−Ｎ−（２，４，６−トリフルオロベンジル）−２，３，４，５，７，９，１３，１３Ａ−オクタヒドロ−２，５−メタノピリド［１’，２’：４，５］ピラジノ［２，１−ｂ］［１，３］オキサゼピン−１０−カルボキサミドの結晶形
JP2019524883A5 (enExample)
CA2950307C (en) Sodium (2r,5s,13ar)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepin-8-olate
JP2013056886A5 (enExample)
JP2016537346A5 (enExample)
JP2017512186A5 (enExample)
JP2014507421A5 (enExample)
JP2014503525A5 (enExample)
JP2014524442A5 (enExample)
JP2010500293A5 (enExample)
JP2018504378A5 (enExample)
JP2020517611A5 (enExample)
JP2017515901A5 (enExample)
JP2013519632A5 (enExample)
ME02612B (me) Tenofovir alafenamid hemifumarat
JP2019504103A5 (enExample)
JP2018521969A5 (enExample)
JP2012526808A5 (enExample)
CN116854745A (zh) 药物共晶组合物及其用途
JP2018521969A (ja) 医薬用共結晶及びその用途
JP2019516749A5 (enExample)
JP2018524320A5 (enExample)
JP6872179B2 (ja) テノホビルプロドラッグの新規な多結晶形並びにその製造方法及び用途
JP2026010129A (ja) Ｈｂｖコアタンパク質アロステリック修飾剤の化合物の固体形態